5.00
price down icon6.02%   -0.32
after-market After Hours: 5.00
loading
Altimmune Inc stock is traded at $5.00, with a volume of 3.59M. It is down -6.02% in the last 24 hours and down -24.81% over the past month. Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$5.32
Open:
$5.07
24h Volume:
3.59M
Relative Volume:
1.48
Market Cap:
$386.61M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.0488
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-17.36%
1M Performance:
-24.81%
6M Performance:
-18.57%
1Y Performance:
-50.88%
1-Day Range:
Value
$4.78
$5.12
1-Week Range:
Value
$4.78
$6.0355
52-Week Range:
Value
$4.78
$11.16

Altimmune Inc Stock (ALT) Company Profile

Name
Name
Altimmune Inc
Name
Phone
(240) 654-1450
Name
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
ALT's Discussions on Twitter

Compare ALT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALT
Altimmune Inc
5.00 386.61M 409.00K -101.35M -71.49M -1.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-28-25 Initiated William Blair Mkt Perform
Jan-08-25 Initiated Stifel Buy
Nov-12-24 Initiated UBS Buy
Apr-29-24 Downgrade Guggenheim Buy → Neutral
Jan-24-24 Initiated Goldman Neutral
Mar-22-23 Downgrade Goldman Buy → Neutral
Dec-01-22 Initiated Goldman Buy
Dec-29-21 Resumed Jefferies Buy
Jun-02-21 Initiated H.C. Wainwright Buy
Feb-11-21 Initiated Guggenheim Buy
Dec-14-20 Initiated Jefferies Buy
Nov-12-20 Reiterated B. Riley Securities Buy
Sep-25-20 Initiated B. Riley FBR Buy
Aug-14-20 Initiated Evercore ISI Outperform
Jul-31-20 Initiated Piper Sandler Overweight
Jul-28-20 Initiated JMP Securities Mkt Outperform
Feb-24-20 Resumed ROTH Capital Buy
Jul-19-19 Initiated ROTH Capital Buy
Oct-09-17 Initiated Piper Jaffray Overweight
View All

Altimmune Inc Stock (ALT) Latest News

pulisher
10:29 AM

PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com

10:29 AM
pulisher
03:35 AM

Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

03:35 AM
pulisher
Mar 22, 2025

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo

Mar 22, 2025
pulisher
Mar 19, 2025

Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey

Mar 19, 2025
pulisher
Mar 17, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha

Mar 17, 2025
pulisher
Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 16, 2025

Altimmune rises as buyout rumors follow R&D updates - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune soars amid takeover speculation - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

(ALT) Trading Advice - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Altimmune to test obesity drug for alcohol use disorder and related health conditions - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 12, 2025
pulisher
Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 09, 2025

Altimmune, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan

Mar 06, 2025
pulisher
Mar 06, 2025

Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire

Mar 05, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains Altimmune stock Buy rating, $12 target By Investing.com - Investing.com Australia

Mar 04, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains Altimmune stock Buy rating, $12 target - Investing.com India

Mar 04, 2025

Altimmune Inc Stock (ALT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):